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Surgery is t�e oldest and most frequent met�od of 
primary treatment for colorectal cancer. Operations of 
cancer are rat�er complicated and usually associated 
wit� blood transfusion to restore normal p�ysiology. 
T�ere is evidence t�at blood transfusion associated 
wit� an increased rate of tumor recurrence and t�at 
decreased t�e survival of cancer patients [1�3]. 
However�� ot�er aut�ors �aven’t found any increase in 
cancer recurrence after perioperative blood transfu-
sion [4�� 5]. 
Perioperative blood transfusions may �ave a delete-
rious effect on t�e survival of cancer patients�� possibly 
because of its immunosuppressive effect [�]. W�et�er 
or not blood transfusion exerts an immunosuppressive 
effect on t�e recipient remains an area of controversy. 
T�e mec�anisms of t�is effect are insufficiently known 
and not fully understood. Dzik et al. �as presupposed 
t�at blood transfusion can stimulate t�e synt�esis of 
t�e immunosuppressive cytokine TGF-β. However�� we 
�ave not found t�e information about t�e c�anges of 
TGF-β after blood transfusion. �iki C et al. [1] �ave 
s�own t�at blood transfusion increased levels of proin-
flammatory cytokine IL-� in blood of colorectal cancer 
patients. However�� we �ave not found literature date 
about t�e c�anges of anot�er important proinflamma-
tory cytokine TNF-α after blood transfusion.
Recently paced red blood cells �RBC�� are more 
often used in transfusion. T�ere are scarce scien-
tific literary data about t�e influence of allogenic RBC 
transfusion on c�anges of immunosupressive TGF-β 
and proinflammatory TNF-α cytokines in colorectal 
cancer patients alt�oug� t�ese cytokines are impor-
tant in neoplasia process [8�11].
T�e aim of our study was to estimate c�anges in 
t�e concentration of cytokines TGF-β1 and TNF-α 
in colorectal cancer patients’ perip�eral blood after 
surgery and allogenic RBC transfusion.
Patients and methods
Forty eig�t patients wit� diagnosed primary 
colorectal cancer in t�e Department of Abdominal Sur-
gery�� Institute of Oncology�� Vilnius University�� Lit�uania 
were involved in t�e study. T�e study was approved 
by t�e local researc� et�ics committee�� and written 
informed consent was obtained from all patients.
Colorectal cancer patients’ eligibility criteria are 
summarized in Table 1. 
Table 1. Colorectal cancer patients’ eligibility criteria
Inclusion criteria: Exclusion criteria: 
Age 45–65 years 
Patients with histological confirmed 
colorectal adenocarcinoma in 
stage III
Without previous blood transfusion
Parameters before surgery: 
Haemoglobin concentration 
> 100 g/L; Haematocrit > 36%;
Platelet count >150 × 109/L 
Weight > 60 kg 
Patients with active infections
Patients with chronic pulmonary, 
chronic active hepatitis and ische­
mic cardiac disease
Patients taking immunosuppressive 
drugs or on chronic anticoagulation
We studied patients wit� �istologically documented 
colorectal adenocarcinoma  in stage III �T1�4N+���� wit� 
ECOG performance status ��� and reasonable �ema-
tology�� liver and renal functions. All patients underwent 
curative operation.
T�e median age of patients was 58 years �range 
of years 45��5��. Among t�em 38 patients were men 
and �� were women. All patients were divided in 
two groups: transfused patients group consisted of 
3� persons �average age 5�.5 ± 3.8 years; 18 men 
and 1� women�� and non-transfused patients group 
consisted of 34 persons �average age 5�.8 ± 3.� years; 
�� men and 14 women��. 
Transfused patients group was considered t�at re-
ceived 1�� packet allogenic RBC intraoperation �blood 
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lost > 5�� ml�� and t�at received 1�� packet allogenic 
RBC wit�in 1�5 days after t�e surgery. Allogenic red 
blood transfusions were administered after operation 
if �aemoglobin dropped to < 1�� g/L and �aematocrit 
values decreased to < �5%.
Venous blood of cancer patients was tested before 
surgery �1st analysis�� as well as � and 14 days after 
surgery ��nd and 3rd analysis�� respectively��.
RBC packets �ave been prepared from w�ole 
blood by removing most of t�e plasma and red blood 
cells suspended in saline-adenine-glucose-mannitol 
�SAG��� in Public Institution National Blood Center of 
Lit�uania. RBC packets �ave been prepared according 
to t�e recommendations of t�e Council of Europe and 
leukocytes count was < 1.�·1��/ L.
Cytokine measurement by ELISA. Perip�eral 
venous blood was obtained from �4 individuals and 
serum was separated. T�e samples were frozen and 
stored at �� °C until assayed. Cytokines TGF-β1 and 
TNF-α concentrations were quantitatively measured 
using ELISA kits obtained from Biosource �Niveles�� 
Belgium�� according to t�e manufacturer’s instructions. 
According to t�e manufacturer�� t�e sensitivity of t�ese 
assays is 15.� pg/ml for TGF-β1 and 3 pg/ml for TNF-α. 
T�e optical density at 45� nm was measured wit� an 
ELISA reader ��ultiskan EX�� Labsystem Oy��.
Hematological parameters. T�e following 
�aematological indices were determined: total eryt�-
rocytes number�� �aemoglobin concentration�� total 
leukocytes number�� granulocyte�� lymp�ocyte and 
platelet count was determined by t�e Abbott Cell Dyn 
1��� �ematology analyzer. Percent values of lymp�o-
cytes�� granulocyte were determined by microscopic 
examination of smears in perip�eral blood stained by 
Pappen�eim met�od ��ay — Grunwald — Giemsa��.
Statistical analysis. Statistical analysis was per-
formed using t�e statistical software SAS version 8.�. 
Paired Student’s t-test was used to compare t�e dif-
ference in cytokines and �aematological parameters in 
perip�eral blood of patients’ before and after operation 
and transfusion. T�e differences of comparative values 
were estimated as reliable at p ≤ �.�5. 
ResULts
Allogenic RBC transfusion can be related to t�e 
variations of cytokines and cellular parameters in t�e 
colorectal cancer patient’s blood. Consequently�� cellu-
lar parameters in perip�eral blood of patients after RBC 
transfusion were analyzed in addition to t�e analysis of 
cytokines TGF-β1 and TNF-α concentration. 
We investigated t�ose indices after �t� ��nd analysis�� 
and 14t� �3rd analysis�� days in post-operational period to 
estimate t�e parameters’ c�anges in dynamics during 
stay in �ospital. All parameters investigated in post-opera-
tional period were compared to t�e appropriate param-
eters detected before t�e treatment �1st analysis��.
Statistical analysis �as s�own t�at serum levels 
of cytokines TGF-β1 and TNF-α didn’t c�ange sig-
nificantly in �nd and 3rd analysis after surgery in non-
transfused patients group �Table ���. 
Table 2. Serum levels of TGF­β1 and TNF­α in non­transfused patients’ 
group
Concentration of cytokines n Analysis1st 2nd 3rd
TGF­β1, ng/mL 34 11.2 ± 1.0 12.0 ± 1.2 13.2 ± 1.2
TNF­α, pg/mL 34 25.1 ± 2.9 30.0 ± 3.0 26.0 ± 2.4
Note: 1st analysis — before operation; 2nd analysis — 7 days after opera­
tion; 3rd analysis — 14 days after operation.
Leukocyte and granulocyte count also didn’t c�ange 
in perip�eral blood of t�at group. Percent and absolute 
count of lymp�ocytes decreased in t�e �nd analysis but 
returned to baseline level in t�e 3rd analysis �Table 3��. 
Table 3. Haematological parameters of peripheral blood 
in  non­transfused patients’ group
Variables n Analysis1st 2nd 3rd
RBC 1012/L 34 4.7 ± 0.11*˚ 4.0 ± 0.13˚ 4.1 ± 0.18*
HB g/L 34 143 ± 3.49*˚ 121 ± 3.44˚ 123 ± 4.45*
Platelets 109/L 34 270 ± 16*˚ 352 ± 30.4˚ 454 ± 44.9*
WBC 109/L 34 7.5 ± 0.59 7.6 ± 0.44 8.0 ± 0.78
Granulocytes % 34 63.9 ± 2.69˚ 72.8 ± 2.13˚ 71.5 ± 2.90
Granulocytes 109/L 34 5.3 ± 0.68 5.5 ± 0.43 6.3 ± 0.80
Lymphocytes % 34 27.4 ± 2.45˚ 19.7 ± 1.96˚ 21.7 ± 1.90
Lymphocytes 109/L 34 1.8 ± 0.11˚ 1.4 ± 0.14˚ 1.6 ± 0.15
˚p ≤ 0.05 (2nd analysis was compared to 1st analysis); *p ≤ 0.05 (3rd 
analysis was compared to 1st analysis); 1st analysis — before operation; 2nd 
analysis — 7 days after operation; 3rd analysis — 14 days after operation.
TGF-β1 concentration significantly increased in t�e 
3rd analysis�� and TNF-α increased in t�e �nd and 3rd 
analysis transfused patients group �Table 4��. 
Table 4. Serum levels of cytokines TGF­β1 and TNF­α in transfused 
patients’ group
Groups Concentration of cytokines n
Analysis
1st 2nd 3rd
Common TGF­β1 (ng/mL) 30 10.1 ± 1.3* 11.8 ± 1.5 15.9 ± 1.7*
TNF­α (pg/mL) 30 20.9 ± 1.7*˚ 32.5 ± 3.1˚ 27.0 ± 2.1*
Patients with 
complication
TGF­β1 (ng/mL) 12 9.3 ± 1.0* 15.0 ± 1.7 16.9 ± 2.0*
TNF­α (pg/mL) 12 21.5 ± 2.1˚ 33.0 ± 3.1˚ 24.5 ± 2.5
Without com­
plication
TGF­β1 (ng/mL) 18 10.7 ± 1.3* 10.7 ± 1.3 15.0 ± 1.6*
TNF­α (pg/mL) 18 20.5 ± 2.1*˚ 31.9 ± 3.2˚ 28.7 ± 2.5*
˚p ≤ 0.05 (2nd analysis was compared to 1st analysis); *p ≤ 0.05 (3rd anal­
ysis was compared to 1st analysis); 1st analysis — before operation; 2nd 
analysis — 7 days after operation; 3rd analysis — 14 days after operation.
Leukocyte and granulocyte count significantly 
increased in transfused patients group �owever lym-
p�ocyte count decreased in t�at group �Table 5��. 
Table 5. Haematological parameters of peripheral blood in transfused 
patients’ group
Variables n Analysis1st 2nd 3rd
RBC 1012/L 30 4.3 ± 0.08*˚ 3.8 ± 0.10˚ 3.9 ± 0.11*
HB g/L 30 122 ± 3.8*˚ 106 ± 2.9˚ 109 ± 2.7*
Platelets 109/L 30 323 ± 41.0*˚ 291 ± 25.0˚ 452 ± 39.4*
WBC 109/L 30 6.7 ± 0.55*˚ 9.6 ± 0.69˚ 9.8 ± 0.74*
Granulocytes % 30 64.1 ± 3.76* 76.0 ± 6.12 75.3 ± 2.04*
Granulocytes 109/L 30 4.4 ± 0.60*˚ 6.9 ± 0.86˚ 6.9 ± 0.73*
Lymphocytes % 30 28.1 ± 2.46*˚ 13.2 ± 1.33˚ 13.4 ± 1.49*
Lymphocytes 109/L 30 1.7 ± 0.19*˚ 1.3 ± 0.20˚ 1.4 ± 0.15*
˚p ≤ 0.05 (2nd analysis was compared to 1st analysis); *p ≤ 0.05 (3rd anal­
ysis was compared to 1st analysis); 1st analysis — before operation; 2nd 
analysis — 7 days after operation; 3rd analysis — 14 days after operation. 
Similar tendencies were observed in t�e ot�er 
�aematological parameters c�anges bot� in non-
transfused and transfused patients group. T�e eryt�-
rocyte count and �aemoglobin level decreased and 
platelet count increased significantly in t�e �nd and 
3rd analysis �Table 3�� 5��.
Postoperative complications �perineum abscess�� 
surgery seam suppuration�� perineum fistula�� were 
observed in 15 from �4 patients: for 1� transfused 
patients and for only 3 non-transfused patients. T�e 
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statistical analysis of data was performed only for t�e 
transfused patients group wit� postoperative compli-
cations because t�e lack of patients wit� complication 
in non-transfused group. 
T�e statistical analysis �as s�own t�at t�e con-
centration of cytokine TNF-α in serum of patients 
wit� complications significantly increased in t�e �nd 
analysis and t�e concentration of t�e cytokine re-
turned to baseline level in t�e 3rd analysis. T�e level 
of cytokine TGF-β1 significantly increased in t�e 3rd 
analysis �Table 4��. 
T�e concentration of cytokine TNF-α significantly 
increased in t�e �nd and 3rd analysis in patients wit�-
out complications. TGF-β1 concentration increased 
only in t�e 3rd analysis in t�e case �Table 4��. 
T�e similar tendency of �aematological parameters 
c�anges was observed in patients bot� wit� and wit�-
out complications. 
disCUssion
T�e results of our study �ave indicated t�at t�e 
c�anges of cytokines TGF-β1 and TNF-α concentra-
tion may be determined by blood transfusion because 
levels of bot� cytokines increased markedly in t�e 
sera of patients after colorectal cancer surgery in t�e 
transfused group and c�anged only insignificantly in 
t�e non-transfused group. 
TGF-β1 is a multipotent cytokine and a potent 
suppressor of immune cells. T�e cytokine plays an 
important role in late-stage carcinogenesis [1�] by 
stimulating t�e invasive be�avior of cancer cells�� 
promoting neo-angiogenesis and �elping cancer 
cells to escape surveillance by t�e immune system 
[11�� 1�]. Narai et al. [13] �ave also s�own t�at TGF-β1 
concentration was significantly �ig�er in patients wit� 
colorectal cancer.  
TNF-α�� anot�er multipotent cytokine�� performs 
several immunologic functions and it is involved in 
maintaining t�e �omeostasis of t�e immune system. 
It is known�� t�at TNF-α�� like IL-1 and IL-��� suppresses 
eryt�ropoesis by direct in�ibitory effects on bone 
marrow RBC production [14]. TNF-α �cac�ectin�� t�at 
probably causes cac�exia and anemia is increased in 
cancer patients and may en�ance tumor growt� and 
invasion [15]�� w�ereas after surgery cytokine TNF-α 
level not elevate in patients wit� rectal cancer [1�].
T�us�� cytokines TGF-β1 and TNF-α are important 
in cancer and t�eir increase after allogenic RBC 
transfusion can influence on negative current of t�e 
disease course.
Leukocyte count increased and lymp�ocyte count 
decreased in t�e �nd analysis of t�e transfused group 
patients and similar tendency remained in t�e 3rd 
analysis. Leukocytes increased at t�e expense of 
granulocytes because t�e total lymp�ocyte count 
was lowered. It seems reasonably to suggest t�at 
w�ite blood cells �ave c�anged as a consequence of 
allogenic RBC transfusion because no significant dif-
ferences between pre- and postoperative leukocyte 
and lymp�ocyte count were found in non-transfused 
patients. Fenwick [1�] and Izbicki [18] �ave s�own 
t�at blood transfusion is t�e cause of leukocytosis in 
critically ill patients. 
Blood transfusion is associated wit� t�e restoration 
of �aemoglobin level and eryt�rocyte count. Allogenic 
RBC transfusion was administered if after operation 
�aemoglobin level decreased below 1�� g/L. After 
transfusion t�e �aemoglobin was restored to a lower 
t�an normal level and remained in t�e same level till 
14 days after operation. Haemoglobin level�� eryt�ro-
cyte and platelet count s�owed a similar tendency of 
c�anges in t�e analysis of t�e transfused and non- 
transfused patients groups. It may be determined by 
operation stress and operation trauma. 
T�us�� t�e quantitative c�anges of TGF-β1 and 
TNF-α�� leukocytes and lymp�ocytes in t�e perip�eral 
blood of colorectal cancer patients after RBC transfu-
sion imply t�at transfusion may �ave a negative influ-
ence on t�e immune system of patients.  
Interestingly�� we observed postoperative complica-
tions �perineal abscess�� surgery seam suppuration�� 
perineal fistula�� in 1� patients from t�e transfused group 
and only in 3 patients from t�e non-transfused group. 
Postoperative complications in t�ose patients often 
developed after 4�� days. T�e cytokine TNF-α level in-
creased at � days after surgery but it returned close t�e 
baseline level after 14 days�� possibly under t�e effects 
of systemic and local anti-inflammatory treatment. T�e 
level of cytokine TGF-β1 significantly increased 14 days 
after operation. All t�e parameters studied in non-
complicated patients c�anged similarly as in t�e blood 
transfusion patients’ group. T�e reason mig�t be t�at 
t�ese post-operative complications are local processes 
and are not reflected in systemic c�anges.
T�e influence of RBC transfusion is complicated. 
It remains unclear w�at p�ysiological conditions or 
stimuli induce postoperative complications in t�e 
transfused patients. 
T�us�� blood transfusion poses a difficult problem 
and t�ere are still many controversial aspects related 
to its benefits. 
Considerably�� more detailed examination is needed 
to evaluate t�e influence of blood transfusion on t�e 
organism of colorectal cancer patients. �oreover�� 
complex investigations of t�e ot�er organism sys-
tems parameters of colorectal cancer patients are 
necessary in perspective to provide a more ex�austive 
answer to t�e problem. It may be t�at allogenic RBC 
administration is not a solution for colorectal cancer 
patients. 
In conclusion�� in our study we �ave found t�at t�e 
level of multipotent cytokines TGF-β1 and TNF-α sig-
nificantly increased after RBC transfusion. T�e data of 
our study corroborate findings of ot�er investigators 
w�o s�owed t�at allogenic RBC transfusion mig�t 
exert immunomodulatory effects. 
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ИЗМЕНЕНИЯ КОНЦЕНТРАЦИИ ТРАНСФОРМИРУЮЩЕГО 
ФАКТОРА РОСТА (ТФР-β1) И ФАКТОРА НЕКРОЗА 
ОПУХОЛИ (ТФР-α) ПОСЛЕ ПЕРЕЛИВАНИЯ 
АЛЛОГЕННОЙ ЭРИТРОЦИТАРНОЙ МАССЫ БОЛЬНЫМ 
КОЛОРЕКТАЛЬНЫМ РАКОМ
Операции больных онкологического профиля нередко сложные и сопровождаются переливанием крови для восстановления 
кровопотери. Данные литературы свидетельствуют о том, что переливание крови оказывает иммуномодулирующий эффект 
на организм пациентов. Однако существует недостаточно данных относительно влияния переливания крови на  изменения 
концентраций цитокинов ТФР-β1 и ФНО-α, играющих важную роль в развитии опухолевой болезни. Цель: определение 
влияния переливания аллогенной эритроцитарной массы на изменения концентрации цитокинов ТФР-β1 и ФНО-α в пери-
ферической крови больных колоректальным раком после операции. Методы: концентрацию цитокинов ТФР-β1 и ФНО-α 
определяли методом ELISA у 64 больных раком толстой кишки III стадии до и после операции.      Результаты: концентрация 
цитокинов ТФР-β1 и ФНО-α достоверно повышалась в периферической крови больных, которым после операции пе-
реливали аллогенную эритроцитарную массу (перед операцией: ТФР-β1 10,1 ± 1,3 ng/ml, ФНО-α 20,9 ± 1,7 pg/ml, 
после операции и переливания массы аллогенных эритроцитов: ТФР-β1 15,9 ± 1,7 ng/ml; ФНО-α 27,0 ± 2,1 pg/ml). 
Выводы: полученные  результаты показали, что концентрация мультипотентных цитокинов ТФР-β1 и ФНО-α повысилась 
у больных колоректальным раком III стадии после переливания аллогенной эритроцитарной массы.       
Ключевые слова: трансформирующий фактор роста-β1, фактор некроза опухоли-α, переливание аллогенной 
эритроцитарной массы. 
